The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation
Clinical Infectious Diseases, 2009•academic.oup.com
In vitro studies have shown possible antiviral effects of tyrosine kinase inhibitors. In a
retrospective study, we show that use of the tyrosine kinase inhibitor imatinib does not
appear to reduce cytomegalovirus reactivation during the first 100 days after transplantation
in a cohort of hematopoietic cell transplant recipients.
retrospective study, we show that use of the tyrosine kinase inhibitor imatinib does not
appear to reduce cytomegalovirus reactivation during the first 100 days after transplantation
in a cohort of hematopoietic cell transplant recipients.
Abstract
In vitro studies have shown possible antiviral effects of tyrosine kinase inhibitors. In a retrospective study, we show that use of the tyrosine kinase inhibitor imatinib does not appear to reduce cytomegalovirus reactivation during the first 100 days after transplantation in a cohort of hematopoietic cell transplant recipients.
Oxford University Press